Activity of the antiarrhythmic drug amiodarone against Leishmania (L.) infantum: an in vitro and in vivo approach

Abstract

BackgroundConsidering the high toxicity and limited therapies available for treating visceral leishmaniasis (VL), the drug repositioning approach represents a faster way to deliver new therapies to the market.MethodsIn this study, we described for the first time the activity of a potent antiarrhythmic, amiodarone (AMD), against L. (L.) infantum and its in vitro and in vivo activity.ResultsThe evaluation against promastigotes has shown that amiodarone presents leishmanicidal effect against the extracellular form, with an IC50 value of 10 μM. The activity was even greater against amastigotes in comparison with promastigotes with an IC50 value of 0.5 μM. The selectivity index in relation to the intracellular form demonstrated that the antiparasitic activity was approximately 56 times higher than its toxicity to mammalian cells. Investigation of the in vivo AMD activity in the L. infantum-infected hamster model showed that 51 days after the initial infection, amiodarone was unable to reduce the parasite burden in the spleen and liver when treated for 10 consecutive days, intraperitoneally, at 50 mg/kg/day, as determined by qPCR. Although not statistically significant, AMD was able to reduce the parasite burden by 20% in the liver when treated for 10 consecutive days, orally, at 100 mg/kg/day; no reduction in the spleen was found by qPCR.ConclusionsOur findings may help further drug design studies seeking new AMD derivatives that may provide new candidates with an in vitro selectivity close to or even greater than that observed in the prototype delivering effectiveness in the experimental model of VL.

Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae)

“…Based on the obtained results in this study, it is possible to suggest that both compounds 1 and 2 are interesting prototypes for the development of new drugs, since these molecules were more selective than the standard drug miltefosine, showing a selective index of 3. Other works found a different range of miltefosine SI against Leishmania species that basically is dependent on the parasite specie, strain and number of parasites in the assays among other reasons.…”

Recent strategies for the development of oral medicines for the treatment of visceral leishmaniasis

“…The efficacies of the repositioned drugs described in the studies were varied. Pinto and Tempone (2018) reported the in vitro efficacy of amiodarone against intracellular L. infantum promastigote and amastigote forms, partly due to its antagonistic activity in calcium channels. In vivo assays in young hamsters orally treated with amiodarone at 50 and 100 mg/kg/day did not show statistically significant results.…”

An overview of the treatment of cutaneous leishmaniasis

“…Amiodarone is a potent antiarrhythmic whose anti-leishmanial activity was reported recently in different studies 47 , 48 . The mechanisms of action as an anti-leishmanial are inhibition of sterol biosynthesis, destabilization of Ca 2+ homeostasis, the collapse of mitochondrial membrane potential, and production of reactive oxygen species 49 , 50 .…”